Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Opdivo
Opdivo
Strike three: Bristol-Myers’ third I/O shot at glioblastoma misses as Opdivo flops yet again on key endpoint
Endpoints
Thu, 09/5/19 - 10:13 am
Bristol-Myers Squibb
Opdivo
glioblastoma
brain cancer
clinical trials
What happened a year ago this week in biopharma? August 12-18, 2018
Mon, 08/19/19 - 11:04 am
Regeneron
Novartis
wet-AMD
Eylea
ethics
Vertex Pharmaceuticals
Kalydeco
cystic fibrosis
Bristol-Myers Squibb
Opdivo
Merck
Keytruda
SCLC
What happened a year ago this week in biopharma? August 12-18, 2018
CP WIre
Sun, 08/18/19 - 04:30 pm
Regeneron
Novartis
wet-AMD
Eylea
ethics
Vertex Pharmaceuticals
Kalydeco
cystic fibrosis
Bristol-Myers Squibb
Opdivo
Merck
Keytruda
SCLC
Anti-PD-1 Drug Opdivo Significantly Improves Five Year Survival In Advanced Cancers
Forbes
Wed, 07/31/19 - 08:57 am
advanced cancer
Opdivo
Bristol-Myers Squibb
advanced melanoma
Sales gap grows between rival Merck, Bristol cancer therapies
Biopharma Dive
Tue, 07/30/19 - 11:33 am
Merck
Keytruda
Bristol-Myers Squibb
Opdivo
cancer
Bristol-Myers’ Rosy Outlook Trumps Trial Setback as Stock Gains
Yahoo/Bloomberg
Thu, 07/25/19 - 10:52 am
earnings
Bristol-Myers Squibb
Opdivo
Bristol, With Another Lung Cancer Flop, Loses More Ground to Merck
Xconomy
Wed, 07/24/19 - 10:20 pm
Bristol-Myers Squibb
Merck
Keytruda
Opdivo
non-squamous
non-squamous non-small cell lung cancer
Bristol-Myers, Ono, Bayer Team Up for Colorectal Cancer Study
Yahoo/Zacks.com
Sat, 07/20/19 - 08:25 pm
Bristol-Myers Squibb
Bayer
Ono Pharmaceutical
Opdivo
Stivarga
metastatic colorectal cancer
Bristol-Myers star Opdivo fails survival test in a matchup with Nexavar aimed at shaking up the big HCC market
Endpoints
Mon, 06/24/19 - 11:25 am
Bristol-Myers Squibb
Opdivo
Bayer
Nexavar
liver cancer
clinical trials
In surprise switch, Bristol-Myers is selling off blockbuster Otezla, promising to complete Celgene acquisition — just later
Endpoints
Mon, 06/24/19 - 11:23 am
Bristol-Myers Squibb
Opdivo
Otezla
M&A
FTC
Celgene
Meet the Top Ten Drugs of 2024 (Maybe)
Drug Channels
Tue, 06/18/19 - 11:46 pm
AbbVie
Humira
Merck
Keytruda
Eliquis
Bristol-Myers Squibb
Imbruvica
Opdivo
Revlimid
Celgene
As Bristol-Myers/Celgene tie up loose ends, BeiGene pockets $150M from PD-1 breakup
Endpoints
Mon, 06/17/19 - 10:06 am
BeiGene
Bristol-Myers Squibb
Celgene
Opdivo
3 takeaways from cancer's biggest conference
Biopharma Dive
Thu, 06/6/19 - 10:03 pm
Amgen
KRAS
accelerated approvals
Turning Point Therapeutics
Keytruda
Opdivo
ASCO 2019
Complete response rate in Nektar melanoma trial hits 34%
Fierce Biotech
Sun, 06/2/19 - 01:12 pm
Nektar
NKTR-214
Opdivo
ASCO 2019
melanoma
Bristol-Myers' Opdivo fails late-stage brain cancer trial
Yahoo/Reuters
Thu, 05/9/19 - 10:45 am
Bristol-Myers Squibb
Opdivo
clinical trials
glioblastoma multiforme
BMS' head and neck cancer hopes take a hit with Opdivo-Yervoy trial flop
Fierce Pharma
Thu, 04/25/19 - 12:01 pm
Bristol-Myers Squibb
head and neck cancer
Opdivo
Yervoy
Nobel laureate behind Bristol's I-O superstar Opdivo demands a bigger cut
Fierce Pharma
Thu, 04/11/19 - 12:27 pm
Opdivo
Bristol-Myers Squibb
Ono Pharmaceutical
R&D
Bristol-Myers details its failure on Checkmate 451, highlighting a bleak future for their checkpoint combo
Endpoints
Thu, 04/11/19 - 10:17 am
Bristol-Myers Squibb
Opdivo
Yervoy
small cell lung cancer
Apexigen's CD40 agonist shows response in pancreatic cancer
BioCentury
Mon, 04/1/19 - 10:41 am
Apexigen
APX005M
Opdivo
pancreatic cancer
Bristol-Myers Squibb's Opdivo-Yervoy duo provokes response in rare tumors
Fierce Pharma
Sun, 03/31/19 - 03:51 pm
Bristol-Myers Squibb
Opdivo
Yervoy
neuroendocrine tumors
Pages
« first
‹ previous
…
2
3
4
5
6
7
8
9
10
…
next ›
last »